The company priced about 6.6 million shares of its common stock at $19 per share, and is offering underwriters an option to purchase additional shares from a selling stockholder.
Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform.
The company said Q1 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.
The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.
The firms are pairing Personalis' comprehensive cancer genomics technology with Indivumed's multiomic database, hoping to improve the insights gleaned from banked samples.
